75P Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): An open-label, single-arm, phase II studyZhiqiang Wang, Yun Zang, Chen Ye et al.|Annals of Oncology|2024Cited by 1